This review offers a comprehensive synthesis of the current evidence on pancreatic stone protein (PSP), highlighting its emerging role as a biomarker across a wide spectrum of clinical conditions from sepsis and intra-abdominal infections to oncological and metabolic diseases. Here, REG1A is linked to metabolic disease.